PepGen (NASDAQ:PEPG) Given New $15.00 Price Target at Guggenheim

PepGen (NASDAQ:PEPG) had its price objective raised by Guggenheim from $7.00 to $15.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim‘s price objective suggests a potential upside of 197.62% from the company’s current price.

A number of other brokerages have also weighed in on PEPG. HC Wainwright reissued a “buy” rating on shares of PepGen in a report on Wednesday, September 9th. Wall Street Zen upgraded PepGen from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Wedbush lifted their price target on PepGen from $4.00 to $10.00 and gave the stock an “outperform” rating in a research report on Wednesday. Bank of America raised PepGen from an “underperform” rating to a “neutral” rating and lifted their price target for the stock from $2.50 to $6.00 in a research report on Tuesday. Finally, Weiss Ratings upgraded PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $11.40.

PepGen Trading Down 4.2%

NASDAQ:PEPG opened at $5.04 on Friday. PepGen has a twelve month low of $1.31 and a twelve month high of $7.80. The company has a market cap of $349.07 million, a PE ratio of -4.71 and a beta of 2.02. The company’s 50 day moving average is $2.77 and its two-hundred day moving average is $2.97.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). As a group, analysts expect that PepGen will post -1.12 EPS for the current fiscal year.

Institutional Trading of PepGen

Several large investors have recently made changes to their positions in PEPG. Group One Trading LLC acquired a new stake in shares of PepGen in the first quarter worth $77,000. Seven Fleet Capital Management LP purchased a new position in shares of PepGen during the first quarter worth $105,000. Rangeley Capital LLC lifted its position in PepGen by 88.1% during the first quarter. Rangeley Capital LLC now owns 68,096 shares of the company’s stock valued at $121,000 after purchasing an additional 31,896 shares during the period. Persistent Asset Partners Ltd acquired a new position in PepGen during the second quarter valued at $171,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in PepGen in the second quarter valued at $202,000. 58.01% of the stock is owned by hedge funds and other institutional investors.

PepGen Company Profile

PepGen is a clinical-stage biotechnology company developing oligonucleotide medicines for people with neuromuscular diseases. Its Enhanced Delivery Oligonucleotide (EDO) platform is designed to help deliver these medicines to muscle tissue. The company’s pipeline includes PGN-EDO51, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping, and PGN-EDODM1, an investigational candidate for myotonic dystrophy type 1.